Efficacy and resistance

The clinical evidence to support ODEFSEY®▼ (emtricitabine / rilpivirine / tenofovir alafenamide) for the treatment of adults with HIV infection is based on:

  • studies conducted with FTC/TAF when given with cobicistat-boosted elvitegravir (EVG/c) as a fixed-dose combination (GENVOYA®▼);1
  • studies of rilpivirine (RPV) when given with TRUVADA® (FTC/TDF) as individual components or as a fixed-dose combination EVIPLERA®,1 and
  • two phase 3, 96-week, randomised, double-blind, active-controlled studies among virologically suppressed adults switching from the TDF-based regimens EVIPLERA® or ATRIPLA®.2,3